CR20210007A - Degradadores selectivos del receptor de estrógeno - Google Patents

Degradadores selectivos del receptor de estrógeno

Info

Publication number
CR20210007A
CR20210007A CR20210007A CR20210007A CR20210007A CR 20210007 A CR20210007 A CR 20210007A CR 20210007 A CR20210007 A CR 20210007A CR 20210007 A CR20210007 A CR 20210007A CR 20210007 A CR20210007 A CR 20210007A
Authority
CR
Costa Rica
Prior art keywords
estrogen receptor
selective estrogen
sup
sub
receptor degraders
Prior art date
Application number
CR20210007A
Other languages
English (en)
Inventor
Jeffrey Daniel Cohen
Almudena Rubio
Daniel Jon Sall
Jolie Anne Bastian
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67470734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20210007(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20210007A publication Critical patent/CR20210007A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Finger-Pressure Massage (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

<p>Se proporcionan novedosos degradadores selectivos del receptor de estrógeno (SERD) de acuerdo con la fórmula, sales aceptables desde el punto de vista farmacéutico de estos y composiciones farmacéuticas de estos, en donde ya sea R1 o R2 se selecciona independientemente de Cl, F, -CF3, o -CH3, y el otro es hidrógeno, y métodos para su uso</p>
CR20210007A 2018-07-12 2019-07-11 Degradadores selectivos del receptor de estrógeno CR20210007A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862697100P 2018-07-12 2018-07-12
PCT/US2019/041334 WO2020014435A1 (en) 2018-07-12 2019-07-11 Selective estrogen receptor degraders

Publications (1)

Publication Number Publication Date
CR20210007A true CR20210007A (es) 2021-02-08

Family

ID=67470734

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210007A CR20210007A (es) 2018-07-12 2019-07-11 Degradadores selectivos del receptor de estrógeno

Country Status (37)

Country Link
US (4) US10654866B2 (es)
EP (2) EP4155310A1 (es)
JP (6) JP6995241B2 (es)
KR (3) KR102589886B1 (es)
CN (2) CN117379428A (es)
AR (3) AR115694A1 (es)
AU (2) AU2019299947B2 (es)
BR (1) BR122023025061A2 (es)
CA (1) CA3105501C (es)
CL (1) CL2021000045A1 (es)
CO (1) CO2021000043A2 (es)
CR (1) CR20210007A (es)
DK (1) DK3820873T3 (es)
EA (1) EA202092975A1 (es)
EC (1) ECSP21001770A (es)
ES (1) ES2933980T3 (es)
FI (2) FI3820873T3 (es)
HR (1) HRP20230009T1 (es)
HU (1) HUE060963T2 (es)
IL (3) IL289871B2 (es)
JO (1) JOP20210005B1 (es)
LT (1) LT3820873T (es)
MA (2) MA53126B1 (es)
MD (1) MD3820873T2 (es)
MX (2) MX2021000375A (es)
MY (1) MY198962A (es)
PE (1) PE20210400A1 (es)
PH (1) PH12021550049A1 (es)
PL (1) PL3820873T3 (es)
PT (1) PT3820873T (es)
RS (1) RS63809B1 (es)
SA (1) SA521421008B1 (es)
SG (1) SG11202100148TA (es)
SI (1) SI3820873T1 (es)
TW (1) TWI702219B (es)
UA (1) UA127507C2 (es)
WO (1) WO2020014435A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3355884T3 (da) 2015-10-01 2021-08-02 Olema Pharmaceuticals Inc Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
MD3820874T2 (ro) * 2018-07-12 2023-05-31 Lilly Co Eli Degradanți selectivi ai receptorului estrogen
CA3144791A1 (en) 2019-07-07 2021-01-14 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists
JP7680438B2 (ja) 2019-10-01 2025-05-20 サノフイ 新規の置換６，７－ジヒドロ－５ｈ－ベンゾ［７］アンヌレン化合物、その製造方法およびその治療的使用
BR112022009705A2 (pt) 2019-12-09 2022-08-09 Sanofi Sa Forma cristalina anidra de um derivado de ácido 7h-benzo[7]anuleno-2-carboxílico, seus usos e processos de preparação, forma sólida, medicamento e composição farmacêutica
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
AU2021366223A1 (en) 2020-10-19 2023-06-22 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
US12595230B2 (en) 2020-10-19 2026-04-07 Sanofi Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
IL303041A (en) * 2020-11-23 2023-07-01 Sanofi Sa Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
KR20230146523A (ko) * 2021-02-16 2023-10-19 제넨테크, 인크. Gdc-9545 및 아베마시클립 또는 리보시클립을 포함하는병용 요법을 사용한 유방암 치료
CN114957114A (zh) * 2021-02-26 2022-08-30 冷志 一种4-溴-3-氯-7-甲氧基喹啉的合成方法
TWI837605B (zh) * 2021-03-09 2024-04-01 美商美國禮來大藥廠 使用serd組合給藥方案治療癌症之方法
CN117042771A (zh) * 2021-03-09 2023-11-10 伊莱利利公司 使用serd给药方案的组合治疗癌症的方法
TWI894443B (zh) * 2021-03-16 2025-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
KR102743629B1 (ko) * 2022-02-01 2024-12-17 일라이 릴리 앤드 캄파니 선택적 에스트로겐 수용체 분해제의 제조 방법
US20240199629A1 (en) * 2022-02-01 2024-06-20 Eli Lilly And Company Processes for the preparation of selective estrogen receptor degraders
CN120051280A (zh) 2022-10-17 2025-05-27 阿斯利康(瑞典)有限公司 用于治疗癌症的serd的组合
KR20250105413A (ko) 2022-11-02 2025-07-08 페트라 파마 코포레이션 질환의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 크로메논 억제제
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer
US20240180893A1 (en) 2022-11-17 2024-06-06 Astrazeneca Ab Methods of treatment of breast cancer
KR20260005985A (ko) 2023-05-05 2026-01-12 일라이 릴리 앤드 캄파니 Er+ 유방암을 갖는 대상체에서 중추 신경계 (cns) 전이를 치료 및 예방하는 데 사용하기 위한 임루네스트란트 또는 그의 염
KR20260010420A (ko) 2023-05-11 2026-01-20 아스트라제네카 아베 암 치료를 위한 parp1 억제제 및 선택적 에스트로겐 분해제의 병용

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
WO2002094788A1 (en) * 2001-05-22 2002-11-28 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
US7329654B2 (en) * 2001-12-19 2008-02-12 Janssen Pharmaceutica N.V. Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
WO2003086394A1 (en) * 2002-04-08 2003-10-23 Merck & Co., Inc. Inhibitors of akt activity
EP1497277A1 (en) * 2002-04-19 2005-01-19 Signal Pharmaceuticals, Inc. Benzopyranone compounds, compositions thereof, and methods of treatment therewith
AU2005207821B2 (en) 2004-01-22 2011-02-10 Eli Lilly And Company Selective estrogen receptor modulators for the treatment of vasomotor symptoms
US20080221163A1 (en) * 2005-01-18 2008-09-11 Jeffrey Alan Dodge Selective Estrogen Receptor Modulators
AR088082A1 (es) * 2011-10-13 2014-05-07 Lilly Co Eli Moduladores selectivos del receptor androgeno
MX2015016171A (es) 2013-06-19 2016-08-08 Seragon Pharmaceuticals Inc Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
CN117865872A (zh) * 2014-12-18 2024-04-12 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
CN107406424B (zh) * 2014-12-18 2020-08-25 豪夫迈·罗氏有限公司 雌激素受体调节剂及其用途
WO2017127442A1 (en) * 2016-01-18 2017-07-27 The Regents Of The University Of California Methods for treating cancer with rorgamma inhibitors
US10125135B2 (en) * 2016-04-20 2018-11-13 Astrazeneca Ab Chemical compounds
WO2018108954A1 (en) 2016-12-12 2018-06-21 F. Hoffmann-La Roche Ag Process for the preparation of 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol
MD3820874T2 (ro) * 2018-07-12 2023-05-31 Lilly Co Eli Degradanți selectivi ai receptorului estrogen
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑

Also Published As

Publication number Publication date
IL280065A (en) 2021-03-01
IL280065B (en) 2022-04-01
FIC20260010I1 (fi) 2026-04-07
JP7241211B2 (ja) 2023-03-16
MA53124B1 (fr) 2023-02-28
WO2020014435A1 (en) 2020-01-16
JP7746496B2 (ja) 2025-09-30
US11117902B2 (en) 2021-09-14
SA521421008B1 (ar) 2022-10-30
SI3820873T1 (sl) 2023-02-28
NZ771718A (en) 2024-05-31
US11634426B2 (en) 2023-04-25
EA202092975A1 (ru) 2021-04-14
US20200347073A1 (en) 2020-11-05
JP2021530484A (ja) 2021-11-11
US10654866B2 (en) 2020-05-19
IL289871B2 (en) 2023-02-01
US20230234960A1 (en) 2023-07-27
JP2025186400A (ja) 2025-12-23
CA3105501C (en) 2023-10-31
MA53124A (fr) 2021-05-19
MX2023006047A (es) 2023-06-02
US11993608B2 (en) 2024-05-28
KR102589886B1 (ko) 2023-10-17
UA127507C2 (uk) 2023-09-13
BR112020025654A2 (pt) 2021-04-06
EP4155310A1 (en) 2023-03-29
EP3820873A1 (en) 2021-05-19
PL3820873T3 (pl) 2023-02-13
FI3820873T3 (fi) 2023-03-02
KR20230148386A (ko) 2023-10-24
US20210403480A1 (en) 2021-12-30
JOP20210005A1 (ar) 2021-01-10
IL289871A (en) 2022-03-01
AU2022203969B2 (en) 2024-02-15
HUE060963T2 (hu) 2023-04-28
KR102550538B1 (ko) 2023-07-04
DK3820873T3 (da) 2022-12-12
JP2023081954A (ja) 2023-06-13
IL295598A (en) 2022-10-01
CO2021000043A2 (es) 2021-01-18
KR20230005404A (ko) 2023-01-09
AU2019299947A1 (en) 2021-01-07
AR134662A2 (es) 2026-03-04
PT3820873T (pt) 2022-12-23
CL2021000045A1 (es) 2021-07-19
CA3105501A1 (en) 2020-01-16
AR134487A2 (es) 2026-01-21
AR115694A1 (es) 2021-02-17
JP2022050591A (ja) 2022-03-30
US20200017516A1 (en) 2020-01-16
JP7557564B2 (ja) 2024-09-27
JP2022037102A (ja) 2022-03-08
CN117379428A (zh) 2024-01-12
MX2021000375A (es) 2021-05-27
HRP20230009T1 (hr) 2023-02-17
BR122023025061A2 (pt) 2024-02-20
RS63809B1 (sr) 2023-01-31
EP3820873B1 (en) 2022-11-23
AU2022203969A1 (en) 2022-06-30
CN112638916A (zh) 2021-04-09
ES2933980T3 (es) 2023-02-15
IL295598B1 (en) 2023-05-01
MA53126A (fr) 2021-05-19
TWI702219B (zh) 2020-08-21
MD3820873T2 (ro) 2023-05-31
IL289871B (en) 2022-10-01
JP6995241B2 (ja) 2022-01-14
CN112638916B (zh) 2023-09-12
KR20210019065A (ko) 2021-02-19
JP7009672B1 (ja) 2022-01-25
MY198962A (en) 2023-10-05
PH12021550049A1 (en) 2021-09-20
JP2024169490A (ja) 2024-12-05
MA53126B1 (fr) 2023-02-28
SG11202100148TA (en) 2021-02-25
AU2019299947B2 (en) 2022-03-17
JOP20210005B1 (ar) 2023-03-28
TW202019935A (zh) 2020-06-01
PE20210400A1 (es) 2021-03-02
LT3820873T (lt) 2023-01-10
IL295598B2 (en) 2023-09-01
ECSP21001770A (es) 2021-02-26
KR102783756B1 (ko) 2025-03-21

Similar Documents

Publication Publication Date Title
MX2023006047A (es) Degradadores selectivos del receptor de estrogeno.
PH12021550048A1 (en) Selective estrogen receptor degraders.
CR20200532A (es) Compuestos de heteroarilo tetracíclicos
MX384752B (es) ANTAGONISTAS SOLUBLES DE RECEPTOR DE C5a (C5aR).
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MY201700A (en) Methods of making incretin analogs
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
CR20220234A (es) Degradadores de moléculas pequeñas de helios y procedimientos de uso
MX2021004000A (es) Derivados de piperidina.
EP4442695A3 (en) 19-homo, 3.alpha.-hydroxy-steroid-20-one compounds for treating cns disorders
MX418519B (es) Inhibidores selectivos de jak1
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MX2021004940A (es) Derivados de piridinil sulfonamida, composiciones farmaceuticas y usos de estos.
PH12019501724A1 (en) Estrogen receptor modulators
MX2024014845A (es) Esteroides neuroactivos no saturados 9(11) y sus metodos de uso
MX2021003232A (es) Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa.
NZ786543A (en) Compounds active towards nuclear receptors
MX2021015727A (es) Derivados de piridin-3-ilo.
MX2021004379A (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
MX2023010823A (es) Degradadores selectivos del receptor de estrogeno.
IL188927A0 (en) Aryloxy quinolines and uses thereof as 5-ht6 modulators
CR20220153A (es) Derivados de 2–azaespiro [3.4] octano como agonistas de m4
PH12022550859A1 (en) 2-azaspiro[3.4]octane derivatives as m4 agonists